MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

The art of saying no in clinical trials goes beyond simply delivering news; it involves maintaining relationships and ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...

Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) has earned an average rating of “Moderate Buy” from the sixteen analysts that are covering the firm, Marketbeat.com reports. Two research ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...